1h Free Analyst Time
The gastric cancer drugs market is forecasted to grow by USD 19.48 billion during 2023-2028, accelerating AT a CAGR of 18.52% during the forecast period. The report on the gastric cancer drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing awareness campaigns for gastric cancer, growing geriatric population, and increasing prevalence of gastric cancer .
The gastric cancer drugs market is segmented as below:
By Route Of Administration
- Injectable
- Oral
By Distribution Channel
- Offline
- Online
By Geography
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the gastric cancer drugs market covers the following areas:
- Gastric cancer drugs market sizing
- Gastric cancer drugs market forecast
- Gastric cancer drugs market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. IT presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Route of Administration
7 Market Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global gastric cancer drugs market: Abbott Laboratories, AbbVie Inc., AROG Pharmaceuticals INC., AstraZeneca Plc, Bayer AG, Biocon Ltd., Blueprint Medicines Corp., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Celltrion Co. Ltd., Dr Reddys Laboratories Ltd., Eisai Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Merck KGaA, Novartis AG, Otsuka Holdings Co. Ltd., Samsung Biologics Co. Ltd., Takeda Pharmaceutical Co. Ltd., and Zydus Lifesciences Ltd..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is increase in number of drug approvals and drug launches."
According to the report, one of the major drivers for this market is the increasing awareness campaigns for gastric cancer.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- AbbVie Inc.
- AROG Pharmaceuticals INC.
- AstraZeneca Plc
- Bayer AG
- Biocon Ltd.
- Blueprint Medicines Corp.
- Boehringer Ingelheim International GmbH
- Bristol Myers Squibb Co.
- Celltrion Co. Ltd.
- Dr Reddys Laboratories Ltd.
- Eisai Co. Ltd.
- Eli Lilly and Co.
- F. Hoffmann La Roche Ltd.
- Merck KGaA
- Novartis AG
- Otsuka Holdings Co. Ltd.
- Samsung Biologics Co. Ltd.
- Takeda Pharmaceutical Co. Ltd.
- Zydus Lifesciences Ltd.
